3 Results for "

hematological parameters

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "hematological parameters" in MCE Product Catalog:

Cat. No.: HY-168878
CAS No.: 3050819-22-9
Target:  

METTL3

Research Areas:  

Cancer

EP652 is a METTL3 inhibitor and antitumor agent with IC50 values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N 6-methyladenosine (m 6A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-W581820
CAS No.: 10030-90-7
Synonyms: Ferrous succinate
Research Areas:  

Cardiovascular Disease

Iron(II) succinate (Ferrous succinate) is an orally active and organic acid iron supplement (ferrous salt). Iron(II) succinate improves hematological parameters in iron-deficiency anemia rats, including hemoglobin, red blood cells, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration. Iron(II) succinate increases serum ferritin, serum iron levels, and transferrin saturation, while decreasing total iron-binding capacity in iron-deficiency anemia rats. Iron(II) succinate reduces the elevated heart, spleen, and kidney coefficients, and increases the decreased liver coefficient in iron-deficiency anemia rats. Iron(II) succinate replenishes the depleted iron content in the liver and spleen of iron-deficiency anemia rats. Iron(II) succinate can be used for the research of iron-deficiency anemia .
loading...
    loading...
Cat. No.: HY-167681
CAS No.: 68020-77-9
Synonyms: Ro 12-4713
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

Carprazidil (Ro 12-4713) is a potent vasodilator with activity in suppressing severe hypertension and mild heart failure. The use of carprazidil may lead to sodium retention and increased heart rate, requiring increased doses of diuretics or beta-blockers in some cases. Carprazidil and mecycline may both cause hirsutism, limiting their long-term use in women. Carprazidil did not cause adverse side effects on hematological parameters, liver, or kidney function .
loading...
    loading...